Last reviewed · How we verify
Ponatinib + Blinatumomab
Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3.
Ponatinib is a tyrosine kinase inhibitor that targets BCR-ABL1, while Blinatumomab is a bispecific monoclonal antibody targeting CD19 and CD3. Used for Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL).
At a glance
| Generic name | Ponatinib + Blinatumomab |
|---|---|
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Drug class | Tyrosine kinase inhibitor, Bispecific monoclonal antibody |
| Target | BCR-ABL1, CD19, CD3 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ponatinib works by inhibiting the BCR-ABL1 tyrosine kinase, which is a protein that is often overactive in certain types of leukemia. Blinatumomab, on the other hand, works by binding to CD19 and CD3, which are proteins found on the surface of B cells, and triggering an immune response against these cells.
Approved indications
- Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)
Common side effects
- Hypertension
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (PHASE2)
- Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia (PHASE2)
- Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (PHASE2)
- A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia (PHASE2, PHASE3)
- Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL (PHASE2)
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT (PHASE2)
- Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ponatinib + Blinatumomab CI brief — competitive landscape report
- Ponatinib + Blinatumomab updates RSS · CI watch RSS
- Gruppo Italiano Malattie EMatologiche dell'Adulto portfolio CI